INTRODUCTION
Late luminal narrowing is the major limitation of percutaneous transluminal coronary angioplasty (PTCA). Restenosis and recurrent restenosis after first and repeated PTCA (re-PTCA) occur in approx. 30 % of patients [1] . A number of clinical characteristics such as advanced age, impaired glucose tolerance and several plasma markers [2, 3] as well as angiographical details, including the severity of coronary lesions [4] , have been shown to be associated with an elevated risk of restenosis. In addition to clinical and angiographic characteristics, genetic factors may contribute to the risk of restenosis. For example, the T allele of the angiotensinogen 235 M/T gene polymorphism has been reported to be associated with the risk of restenosis as well as recurrent restenosis after PTCA [5, 6] .
An activated clotting system contributes to the development of late luminal narrowing after PTCA. It has been shown [7, 8] that elevated plasma fibrinogen and plasminogen activator-inhibitor-1 (PAI-1) levels can predict restenosis. A number of genetic factors that influence haemostasis have been identified [9] [10] [11] [12] , including the β-fibrinogen − 455 G/A, glycoprotein (GP) IIIa PlA1/ PlA2, PAI-1 4G/5G and factor V Leiden 1691 G/A gene polymorphisms. β-Fibrinogen − 455 G/A, GP IIIa PlA1/PlA2 and PAI-1 4G/5G genotypes have been described to be associated with coronary artery disease (CAD) and myocardial infarction [13] [14] [15] . Factor V Leiden 1691 G/A gene polymorphism has been reported to be associated with deep venous thrombosis, but not with CAD [16] . It has also been reported [17] that factor V Leiden may contribute to early graft occlusion after coronary artery bypass graft operation.
The pathogenesis of atherosclerosis has an inflammatory component with cytokines such as interleukin (IL)-1α and -1β as well as tumour necrosis factor α (TNFα) playing an important role [18, 19] . Increased expression of IL-1α and IL-1β has been shown in patients with restenosis [20, 21] . The genes of these cytokines harbour single nucleotide polymorphisms: IL-1α − 889 C/T, IL-1β − 511 C/T, TNFα −308 G/A and TNFα − 238 G/A [22] [23] [24] [25] . Several studies [25] [26] [27] [28] [29] [30] have investigated possible associations between these gene polymorphisms and CAD, mostly with negative results [25] [26] [27] [28] 30] .
It has been shown [31] that patients with restenosis after PTCA have significantly higher plasma homocysteine levels than patients without restenosis. Homocysteine is remethylated to methionine by the enzyme methylenetetrahydrofolate reductase (MTHFR). The MTHFR gene contains a C/T gene polymorphism at position 677. The MTHFR 677 TT genotype is associated with mild hyperhomocysteinaemia, and it is currently a matter of debate whether or not the MTHFR 677 TT genotype is associated with CAD [32, 33] .
Nitric oxide (NO), synthesized by endothelial NO synthase (eNOS) [34] , is an important vascular relaxant [35] that also inhibits smooth muscle cell proliferation [36] and platelet, as well as leucocyte, adhesion to the endothelium [37, 38] . NO may play a protective role against restenosis after PTCA [39] . Intron 4 of the eNOS gene has a tandem repeat polymorphism of two alleles, one containing four and the other five repeats (4a and 4b respectively) [40] . The presence of the rare 4a allele has been reported [40] to be associated with CAD.
The present analysis was performed to test for possible associations between the β-fibrinogen − 455 G/A, GP IIIa PlA1/PlA2, PAI-1 4G/5G, Factor V Leiden 1691 G/A, TNFα − 238 G/A, TNFα − 308 G/A, IL-1α − 889 C/T, IL-1β − 511 C/T, MTHFR 677 C/T and eNOS 4 b/a gene polymorphisms and the risk of restenosis after PTCA as well as recurrent restenosis after re-PTCA.
METHODS
The initial cohort comprised PTCA patients with single or multi-vessel CAD who participated in a routine follow-up program of cardiac catheterization. The study population was identical with that described previously [5] . Patients were recruited at the time of follow-up angiography. Study entry criteria were primary balloon angioplasty on a single native coronary vessel within the preceding 6 months. Between August 1995 and October 1997, 1945 patients underwent PTCA without stenting and 292 patients received stents. Patients with stents and patients with re-PTCA interventions were initially excluded from the study. After successful intervention, follow-up angiography was recommended by therapists according to clinical and angiographical criteria. Follow-up angiograms were available in 1061 of the PTCA patients. Angiograms of 247 patients obtained after multiple interventions or PTCA of bypass grafts were excluded. A further 155 patients refused their participation in the study and 82 patients were excluded for incomplete clinical or angiographical data sets. In all, data from 511 out of the remaining 577 patients (88.6 %) were available for the present study. All patients were residents of Western Pomerania, a small area located in the north east of Germany. Clinical and laboratory data were obtained from medical reports.
This research has been carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association. The study was approved by the Institutional Review Committee of the University of Greifswald. Prior to inclusion in the study, all subjects had given informed consent.
PTCA and re-PTCA procedures were carried out by experienced interventional cardiologists as described previously [5, 6] . Dilated vessels were classified according to the American Heart Association/American College of Cardiology (AHA/ACC) criteria [41] . PTCA procedures were considered successful when the residual luminal narrowing in the dilated segment, immediately after PTCA and re-PTCA, was less than 50 %. Restenosis and recurrent restenosis were defined as a > 50 % progression of the residual stenosis at the time of followup angiography compared with the findings immediately following PTCA and re-PTCA respectively.
Genetic analyses
Genetic analyses were performed by laboratory personnel who were blinded from the clinical data. Genomic DNA was extracted from peripheral blood leucocytes using a commercially available kit (High Pure PCR Template Preparation Kit; Roche Diagnostics GmbH, Mannheim, Germany). Genotyping of all gene polymorphisms was performed using a PCR/restrictionfragment-length-polymorphism-based technique. In a few cases, DNA was not available or genotyping was unsuccessful for other reasons. The numbers of genotyped patients for each gene polymorphism under investigation are given below.
The 5 -flanking region and the first exon of the β-fibrinogen gene was amplified using PCR and digested with the HaeIII isoschizomer BsuRI (n = 511) [42] . For determination of the GP IIIa PlA1/PlA2 genotypes, a 268 bp sequence containing exon 2 of the GP IIIa gene was amplified by PCR and digested with MspI (n = 511) [43] . The PAI-1 4G/5G gene polymorphism was genotyped by the use of allele-specific primers (n = 511) [44] . The presence of the factor V Leiden mutation 1691 G/A was determined by PCR and MnlI digestion (n = 498) [45] . The G/A polymorphism at position − 238 of the promoter region of TNFα was defined by PCR and BamHI cleavage of the resulting 192 bp PCR product (n = 511) [46] . The − 308 G/A polymorphism in the TNFα gene promoter was analysed by PCR amplification and digestion of the resulting 223 bp amplicon with the restriction enzyme StyI (n = 511) [47] . Determination of the IL-1α − 889 C/T genotypes was performed by PCR and digestion of the 99 bp PCR product with NcoI (n = 511) [48] . For analysis of the sequence variant − 511 C/T in the IL-1β gene, a specific 304 bp PCR product was generated and treated with AvaI (n = 506) [48] . For analysis of the MTHFR 677 C/T gene polymorphism, PCR and HinfI digestion was performed (n = 511) [49] . The 27 bp repeat polymorphism in the eNOS gene (eNOS 4 b/a polymorphism) was analysed by PCR amplification and size determination of the PCR products by agarose-gel electrophoresis (n = 511) [50] . The smaller allele, a, was a 393 bp product, whereas the larger allele, b, gave a 420 bp PCR product. All digested samples were electrophoresed in 4 % (w/v) agarose gels and visualized by ethidium bromide staining.
Statistics
Data on qualitative characteristics are expressed as percentage values or absolute numbers as indicated. Patients were divided into two groups with respect to the absence or presence of restenosis and recurrent restenosis respectively. Comparisons between groups were made with χ 2 test. Binary logistic regression analysis (dichotomized outcome variable) and multi-variable analysis of co-variance (continuous outcome variable) were used to evaluate independent risk factors for restenosis and recurrent restenosis. Factors considered were clinical and angiographical parameters that have been reported to be associated with restenosis after PTCA and the gene polymorphisms under investigation. With most gene polymorphisms investigated, allele frequencies were high enough to form three genotype groups for inclusion in the logistic regression analysis. In case of less than ten patients being homozygous for the rare allele (GP IIIa PlA1/PlA2, factor V Leiden 1691 G/A, TNFα − 238 G/A and eNOS 4 b/a), two groups were formed with the absence or presence of the rare allele as group variable. A value of P < 0.05 was considered statistically significant.
A post-hoc biometric analysis was performed to assess the quality of the present study design. Patients were divided into two groups according to the absence (group 1, n = 351) or presence (group 2, n = 160) of restenosis. The group 1 proportion π 1 was given by the rate of the genotypes with the rare allele within the non-restenosis group. A two group continuity corrected χ 2 test with a two-sided 0.05 significance level and a statistical power of 80 % was used to compute the minimum rate of genotypes with the rare allele within the restenosis group (group 2 proportion π 2 ), the minimum genotype rate difference ( π = π 2 − π 1 ) and the minimum odds ratio [OR = π 2 (1 − π 1 )/π 1 (1 − π 2 )] that would have been detected with the current study design.
All statistical analyses were performed with SPSS (SPSS GmbH, Munich, Germany) software. Biometric analyses were performed with nQuery study planning software (Statistical Solutions Ltd, Cork, Ireland).
RESULTS
Of the 511 patients in the study, 160 (31.3 %) developed restenosis within 4-6 months after first PTCA. Re-PTCA was successfully performed in 154 patients, and of these patients, 24 received coronary stents and were excluded from further analyses. One patient died of a myocardial infarction 2 days after re-PTCA. Of the remaining 129 patients, 123 underwent follow-up angiography 4-6 months after re-PTCA. Recurrent restenosis was observed in 35 of these patients (28.5 %).
Clinical and angiographical characteristics of patients are given elsewhere [5, 6] . Deviations from the HardyWeinberg equilibrium were detected for the GP IIIa PlA1/PlA2, PAI-1 4G/5G and TNFα − 308 G/A gene polymorphisms in the total initial CAD patient sample and in patients without restenosis, as well as for the TNFα − 308 G/A polymorphism in patients with restenosis. Deviations from the Hardy-Weinberg equilibrium were also detected for the β-fibrinogen − 455 G/A, factor V Leiden 1691 G/A, TNFα − 238 G/A and IL-1α − 889 C/T polymorphisms in the recurrent restenosis and no recurrent restenosis groups.
The distribution of the investigated genotypes did not differ between patients with or without restenosis after first PTCA (Table 1) . Furthermore, the distribution of the investigated genotypes did not differ between patients with or without recurrent restenosis after Table 2) . Additional analyses with an alternative definition of restenosis (> 50 % stenosis at the time of follow-up angiography) as an endpoint also failed to reveal an association between any of the investigated gene polymorphisms and the risk of restenosis after PTCA and recurrent restenosis after re-PTCA respectively (results not shown).
The post-hoc power analysis revealed that, depending on the given rate of genotypes with the rare allele in patients without restenosis, the study would have been able to detect a minimum genotype rate difference between the restenosis and no restenosis groups of 7-13 %. The lowest odds ratios that would have been detectable were between 1.7 and 1.8 for most of the investigated gene polymorphisms. For gene polymorphisms with low frequencies of the rare allele of < 10 % (factor V Leiden 1619 G/A and TNFα − 238 G/A), the minimum detectable odds ratios were 2.3 and 2.6 respectively.
DISCUSSION
Genetic factors are increasingly recognized as important determinants of the risk of restenosis after PTCA. Our present study did not reveal independent and consistent associations between the investigated candidate genes and the risk of restenosis and recurrent restenosis after PTCA. To our knowledge, this is the first study to test for possible associations between the β-fibrinogen − 455 G/A, factor V Leiden 1691 G/A, TNFα A recent meta-analysis [51] included two studies which tested for a possible association between the GP IIIa PlA1/PlA2 genotype and the risk of restenosis after PTCA. The results of this analysis are consistent with our finding that there was no association between the GP IIIa gene polymorphism and the risk of restenosis. An additional analysis of four studies which investigated associations between this genetic factor and the outcome after coronary stenting revealed that patients with the PlA2 allele had a worse outcome than patients with the PlA1/PlA1 genotype [51] . Unfortunately, the definition of outcome variables used in the analysed studies was rather heterogeneous, ranging from early thrombotic stent occlusion to the 6 month incidence of restenosis, thereby limiting the generalizability of the results.
A recent study [52] yielded inconsistent results concerning the relationship between the PAI-1 5G/5G genotype and the risk of restenosis after coronary stenting. Although there was a significant association between the PAI-1 5G/5G genotype and increased late lumen loss in the subgroup of smokers [52] , the contrary result, namely an association of the PAI-1 5G/5G genotype with less late lumen loss, was found in non-smokers [52] . These inconsistent results may be explained by geneenvironmental interactions that may act differently in smokers and non-smokers. Furthermore, the potential pitfalls of post-hoc subgroup analyses need to be considered. It has been convincingly demonstrated recently [53] that selection and publication biases may account for artefactual associations between genetic factors and the risk of restenosis.
Our present findings that the IL 1α − 889 C/T and IL 1β − 511 C/T gene polymorphisms were not associated with restenosis is in agreement with the results of a recent study [54] . Further results from this [54] and another [55] study show that allele 2 at position 2018 of the IL-1 receptor antagonist gene may be protective against restenosis after PTCA and coronary stenting, suggesting that inflammatory processes may be involved in the development of restenosis.
We did not find an association between the MTHFR 677 C/T gene polymorphism and the risk of restenosis and recurrent restenosis after PTCA. This is consistent with the results from several other studies [56] [57] [58] . Also, in agreement with these findings, a study [59] with intravascular ultrasound after coronary stenting revealed no significant association between the MTHFR 677 T allele and the extent of late luminal narrowing. However, there was an association between the MTHFR 677 T allele and the intimal hyperplasia area [59] . Unfortunately, the study [59] was rather small and the finding has not yet been confirmed.
Our present data show an independent association between restenosis and the severity of the lesion according to the AHA/ACC classification. This is consistent with previous findings from other studies [60] [61] [62] . Additionally, the extent of stenosis before and immediately after PTCA were independent predictors of restenosis after PTCA. This is also in good agreement with previous findings [60] .
The present study has several limitations, including limited statistical power, incomplete follow-up and deviations of the genotype distribution of several gene polymorphisms from the Hardy-Weinberg equilibrium in the study population. The total sample size of 511 patients, with 160 patients having restenosis, would have been sufficient to detect a minimal difference of genotype rates between the restenosis and the no restenosis groups of 7-13 % and a minimal odds ratio of 1.7-1.8 for most of the investigated gene polymorphisms with an 80 % statistical power and a 0.05 two-sided significance level. Under these conditions, a true increase in the risk of restenosis of < 70 % related to any of the gene polymorphisms under investigation would have probably been missed. Thus we cannot exclude that one or the other of the genotypes that we investigated may be associated with a potentially relevant increase in the risk of restenosis after PTCA.
Patients were recruited at the time of follow-up angiography after PTCA without stenting. Of the 577 PTCA patients that fulfilled all inclusion criteria and were not excluded for specific reasons, 511 (88.6 %) were available for inclusion in our present study. Of the 130 eligible re-PTCA patients, 123 (94.6 %) were available for the study. Given these high rates of patient availability, we consider it unlikely that incomplete follow-up could have masked a true genotype-related increase in the risk of restenosis after PTCA in our present study.
In our initial study population, the distribution of several genotypes deviated from the Hardy-Weinberg equilibrium. This is most probably explained by a selection bias, since we exclusively recruited patients that had CAD severe enough to warrant PTCA. Although our present study was not designed to test for possible associations between specific gene polymorphisms and CAD, there is evidence from the literature that the gene polymorphisms, which deviated from the HardyWeinberg equilibrium in our present study population, may be associated with atherosclerosis and CAD [14, 15, 18, 29] .
In the present study, there was no association between the β-fibrinogen − 455 G/A, GP IIIa PlA1/A2, PAI-1 4G/5G, factor V Leiden 1691 G/A, TNFα − 238 G/A, TNFα − 308 G/A, IL-1α − 889 C/T, IL-1β − 511 C/T, MTHFR 677 C/T and the eNOS 4 b/a genotypes and the risk of restenosis after PTCA as well as recurrent restenosis after re-PTCA. Our present study confirms that the severity of the lesion as well as the extent of stenosis before and immediately after PTCA are important predictors of restenosis.
